pyronaridine
Phase 2- Indications
- Acute lymphoblastic leukemia, Acute myeloid leukemia
Company intelligence / Profile preview
Armaceutica, Inc.
El Paso, Texas, United Statesarmaceutica.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase 2 study evaluating pyronaridine as an add-on therapy in adults with acute lymphoblastic leukemia and acute myeloid leukemia, comparing survival lengths between subjects receiving pyronaridine versus placebo. The drug shows promise in selectively killing cancer cells while being well-tolerated with minimal side effects compared to traditional chemotherapies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Armaceutica, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Armaceutica, Inc..